Publicaciones en las que colabora con CRISTINA NIETO JIMENEZ (19)

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

2021

  1. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14

  2. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

  3. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  2. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome

    OncoImmunology, Vol. 8, Núm. 10

  3. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors

    PLoS ONE, Vol. 14, Núm. 4

  4. Mapping Bromodomains in breast cancer and association with clinical outcome

    Scientific Reports, Vol. 9, Núm. 1

  5. Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models

    ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014

2018

  1. Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene

    PLoS ONE, Vol. 13, Núm. 11

2017

  1. BET inhibitors as novel therapeutic agents in breast cancer

    Oncotarget, Vol. 8, Núm. 41, pp. 71285-71291

  2. DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer

    Oncotarget, Vol. 8, Núm. 38, pp. 62834-62841

  3. Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors

    Oncotarget, Vol. 8, Núm. 13, pp. 21733-21740

  4. Neutrophils in cancer: Prognostic role and therapeutic strategies

    Molecular Cancer, Vol. 16, Núm. 1

  5. Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer

    Molecular Cancer Therapeutics, Vol. 16, Núm. 11, pp. 2552-2562

  6. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors

    Oncotarget, Vol. 8, Núm. 12, pp. 19478-19490

2016

  1. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: Role of mitotic kinases

    Oncotarget, Vol. 7, Núm. 16, pp. 22865-22872